Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 5/31/26 | Akeso (9926) | Idafang for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/31/26 | Jiangsu Hengrui Pharmaceuticals (600276:SS) | Avida for Colorectal Cancer (CRC) | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/30/26 | Incyte (INCY) | Monjuvi for Diffuse Large B-Cell Lymphoma (DLBCL) - NHL | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/30/26 | Roche (RO) | Columvi for Mantle Cell Lymphoma - NHL | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/30/26 | AbbVie (ABBV) | Temab-A for Solid Tumors | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/08/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/17/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |